FDA Approval Will Unlock New Sleep Market Opportunities

Shared on01 May 25
Fair value Increased 4.75%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on24 Apr 25

AnalystConsensusTarget has decreased profit margin from 3.1% to 2.6% and increased future PE multiple from 193.7x to 228.2x.

Shared on17 Apr 25
Fair value Decreased 28%

AnalystConsensusTarget has decreased future PE multiple from 259.7x to 193.7x.

Shared on09 Apr 25
Fair value Increased 19%

AnalystConsensusTarget has increased future PE multiple from 207.7x to 259.7x.